Tags

Type your tag names separated by a space and hit enter

Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
Expert Rev Anticancer Ther. 2006 Jun; 6(6):849-59.ER

Abstract

Patients with all stages of primary breast cancer are at continuing risk of relapse following 5 years of adjuvant tamoxifen therapy, even in the absence of lymph node involvement. Tamoxifen has been the standard therapy for reducing risk of recurrence, although more than 50% of relapses and deaths occur after completion of tamoxifen. Tamoxifen use is associated with an increased risk of serious side effects, and extended use beyond 5 years may have a negative impact on disease-free survival. Extended adjuvant letrozole therapy confers a significant benefit in relapse-free survival. The approval of letrozole for this indication in the USA and in many European countries introduces a new, safe and effective treatment for disease-free patients seeking to reduce their long-term risk of recurrence.

Authors+Show Affiliations

Dixon JM
Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU, UK. jmd@ed.ac.uk

MeSH

Antineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantClinical Trials as TopicDisease-Free SurvivalDrug Administration ScheduleFemaleHumansLetrozoleLymphatic MetastasisNeoplasm Recurrence, LocalNitrilesTamoxifenTriazoles

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16761928

Citation

Dixon, J Michael. "Extended Adjuvant Therapy With Letrozole: Reducing the Risk of Recurrence." Expert Review of Anticancer Therapy, vol. 6, no. 6, 2006, pp. 849-59.
Dixon JM. Extended adjuvant therapy with letrozole: reducing the risk of recurrence. Expert Rev Anticancer Ther. 2006;6(6):849-59.
Dixon, J. M. (2006). Extended adjuvant therapy with letrozole: reducing the risk of recurrence. Expert Review of Anticancer Therapy, 6(6), 849-59.
Dixon JM. Extended Adjuvant Therapy With Letrozole: Reducing the Risk of Recurrence. Expert Rev Anticancer Ther. 2006;6(6):849-59. PubMed PMID: 16761928.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Extended adjuvant therapy with letrozole: reducing the risk of recurrence. A1 - Dixon,J Michael, PY - 2006/6/10/pubmed PY - 2006/6/21/medline PY - 2006/6/10/entrez SP - 849 EP - 59 JF - Expert review of anticancer therapy JO - Expert Rev Anticancer Ther VL - 6 IS - 6 N2 - Patients with all stages of primary breast cancer are at continuing risk of relapse following 5 years of adjuvant tamoxifen therapy, even in the absence of lymph node involvement. Tamoxifen has been the standard therapy for reducing risk of recurrence, although more than 50% of relapses and deaths occur after completion of tamoxifen. Tamoxifen use is associated with an increased risk of serious side effects, and extended use beyond 5 years may have a negative impact on disease-free survival. Extended adjuvant letrozole therapy confers a significant benefit in relapse-free survival. The approval of letrozole for this indication in the USA and in many European countries introduces a new, safe and effective treatment for disease-free patients seeking to reduce their long-term risk of recurrence. SN - 1744-8328 UR - https://www.unboundmedicine.com/medline/citation/16761928/Extended_adjuvant_therapy_with_letrozole:_reducing_the_risk_of_recurrence_ DB - PRIME DP - Unbound Medicine ER -